Cellis is advancing a pipeline of macrophage-based therapies for solid tumors. Our lead candidate, MDC-735, is in clinical development for local and systemic administration, targeting glioblastoma, head and neck cancers, lung cancer, and platinum-resistant ovarian cancer. MDC-PAN and MDC-IMMUNO are progressing through pre-clinical stages, addressing pancreatic and immunologically cold tumors. With a strong scientific foundation, we are pioneering new treatment options for hard-to-treat cancers.